Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
Planned Parenthood of Indiana has launched a campaign to capitalize on the small but growing number of men who use its 34
health centers around the state.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
The Indiana chapter of the Arthritis Foundation works to improve lives through leadership in the prevention, control and cure
of arthritis and related diseases.
My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local doctors.
I’m here to plead with all men and the people who love them: Don’t be lazy like I was about getting annual PSA checks
and physical exams.
Anti-smoking advocates are organizing a new attempt to strengthen Indianapolis’ ban against smoking in the workplace.
The Indiana General Assembly should pass a bill into law that bans smoking in public places.
Dr. Francis Price Jr. has brought hundreds of eye surgeons to Indianapolis to train them in how to use
a new cornea transplant technique that has swept the ophthalmology field—DSEK, which stands
for Descemet’s stripping endothelial keratoplasty.
Nathan’s Battle Foundation, led by Phil Milto–who has two sons afflicted with the disease–has evolved over 10 years into
what Milto calls a not-for-profit biotech company that has raised money and guided research that resulted in a promising treatment
for Batten disease. Now, some of the gene therapy techniques researchers developed are being applied to other disorders.
Clarian Health this decade has transformed its transplant program into one of the busiest in the country. Its team of surgeons
takes calls around the clock if a viable organ becomes available. They will hop on a charter plane to check out an organ other
doctors don’t want.
